Abdalla MMI. Role of visfatin in obesity-induced insulin resistance. World J Clin Cases 2022; 10(30): 10840-10851 [PMID: 36338223 DOI: 10.12998/wjcc.v10.i30.10840]
Corresponding Author of This Article
Mona Mohamed Ibrahim Abdalla, MSc, PhD, Senior Lecturer, Physiology Department, Human Biology Division, School of Medicine, International Medical University, No. 126, 19 Jln Jalil Perkasa, Kuala Lumpur 57000, Bukit Jalil, Malaysia. monamohamed@imu.edu.my
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 26, 2022; 10(30): 10840-10851 Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.10840
Role of visfatin in obesity-induced insulin resistance
Mona Mohamed Ibrahim Abdalla
Mona Mohamed Ibrahim Abdalla, Physiology Department, Human Biology Division, School of Medicine, International Medical University, Kuala Lumpur 57000, Bukit Jalil, Malaysia
Author contributions: Abdalla MMI collected the data and wrote the paper.
Conflict-of-interest statement: The author declares no conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mona Mohamed Ibrahim Abdalla, MSc, PhD, Senior Lecturer, Physiology Department, Human Biology Division, School of Medicine, International Medical University, No. 126, 19 Jln Jalil Perkasa, Kuala Lumpur 57000, Bukit Jalil, Malaysia. monamohamed@imu.edu.my
Received: April 30, 2022 Peer-review started: April 30, 2022 First decision: May 29, 2022 Revised: June 13, 2022 Accepted: September 23, 2022 Article in press: September 23, 2022 Published online: October 26, 2022
Abstract
The growing worldwide burden of insulin resistance (IR) emphasizes the importance of early identification for improved management. Obesity, particularly visceral obesity, has been a key contributing factor in the development of IR. The obesity-associated chronic inflammatory state contributes to the development of obesity-related comorbidities, including IR. Adipocytokines, which are released by adipose tissue, have been investigated as possible indicators of IR. Visfatin was one of the adipocytokines that attracted attention due to its insulin-mimetic activity. It is released from a variety of sources, including visceral fat and macrophages, and it influences glucose metabolism and increases inflammation. The relationship between visfatin and IR in obesity is debatable. As a result, the purpose of this review was to better understand the role of visfatin in glucose homeostasis and to review the literature on the association between visfatin levels and IR, cardiovascular diseases, and renal diseases in obesity.
Core Tip: Visfatin is an adipocytokine that is produced by visceral fat and other sources. It has been shown to influence glucose and lipid metabolism, as well as enhance the chronic inflammatory state linked to obesity. The findings on the relationship between visfatin and IR in obese patients are controversial. This review aims to better understand how visfatin contributes to the emergence of IR and to assess the possibility of utilizing visfatin levels as a biomarker for the early detection of IR and IR-related diseases, including cardiovascular and renal diseases.
